GGrantIndex
← Leaderboards

Dorothy A Sipkins

Duke University

$8,543,606
Attributed
$8,543,606
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.4M · FY200625
$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,543,606 · 6

By mechanism

R01$5,182,031 · 3
DP2$2,302,500 · 1
K08$649,620 · 1
R21$409,455 · 1

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Bone Marrow

Research focus

Bone MarrowCellsCell SurfaceNeoplasm MetastasisSignal TransductionMolecularAreaBlood VesselsIn VitroIn VivoPreventLaboratoriesLeukemiaSiteIntegrinsStem CellsPathway InteractionsBaseCancer CellCytotoxic ChemotherapyCell MotilityMalignant Breast NeoplasmBreast Cancer CellMediating

Grant awards (22)

Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis$520,653
R01 · FY2025 · CA · contact PI
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis$494,502
R01 · FY2024 · CA · contact PI
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis$335,505
R01 · FY2024 · CA · contact PI
Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis$519,766
R01 · FY2023 · CA · contact PI
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis$349,413
R01 · FY2023 · CA · contact PI
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis$352,969
R01 · FY2022 · CA · contact PI
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia$221,286
R21 · FY2022 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$155,010
R01 · FY2022 · CA · contact PI
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis$362,776
R01 · FY2021 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$215,764
R01 · FY2021 · CA · contact PI
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia$188,169
R21 · FY2021 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$375,447
R01 · FY2020 · CA · contact PI
Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis$367,335
R01 · FY2020 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$366,709
R01 · FY2019 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$380,691
R01 · FY2018 · CA · contact PI
Defining the Rules of Breast Cancer Cell Traffic Through Bone$385,491
R01 · FY2017 · CA · contact PI
Imaging cell homing and engraftment in the bone marrow$129,924
K08 · FY2010 · CA · contact PI
Imaging cell homing and engraftment in the bone marrow$129,924
K08 · FY2009 · CA · contact PI
Imaging cell homing and engraftment in the bone marrow$129,924
K08 · FY2008 · CA · contact PI
Stem cell, tumor and bone marrow microenvironment cross-talk in vivo$2,302,500
DP2 · FY2007 · OD · contact PI
Imaging cell homing and engraftment in the bone marrow$129,924
K08 · FY2007 · CA · contact PI
Imaging cell homing and engraftment in the bone marrow$129,924
K08 · FY2006 · CA · contact PI